Prognostic value of the modified multiple myeloma comorbidity index in real clinical practice
Background. An increase in the number of patients with multiple myeloma (MM) necessitates the creation of reliable tools for assessing their somatic status (comorbidity) in order to personalize the optimal treatment regimen that helps to minimize its toxicity, improves survival and patients quality...
Main Authors: | N. V. Skvortsova, I. B. Kovynev, A. B. Loginova, K. V. Halzov, T. I. Pospelova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2020-10-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/431 |
Similar Items
-
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study
by: Gang Li, et al.
Published: (2023-12-01) -
Somatic comorbidity and the progression of cognitive impairment
by: Leszek Bidzan, et al.
Published: (2023-11-01) -
The importance of serum immunoglobulin free light chain assessment for predicting outcome in patients with newly diagnosed multiple myeloma in real clinical practice
by: N. V. Skvortsova, et al.
Published: (2020-10-01) -
Olfactory Decline in Older Adults with Mild Cognitive Impairment with and without Comorbidities
by: Katerina Touliou, et al.
Published: (2021-11-01) -
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors
by: Laura Gengenbach, et al.
Published: (2021-08-01)